pyridostigmine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
acetylcholinesterase inhibitors 2330 155-97-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • pyridostigmine
  • pyridostigmine bromide
  • pyridostigmine iodide
A cholinesterase inhibitor with a slightly longer duration of action than NEOSTIGMINE. It is used in the treatment of myasthenia gravis and to reverse the actions of muscle relaxants.
  • Molecular weight: 181.21
  • Formula: C9H13N2O2
  • CLOGP: -4.26
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 0
  • TPSA: 33.42
  • ALOGS: -2.32
  • ROTB: 2

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.18 g O
10 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 100 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 85 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 76.59 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 7.60 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.10 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 9.60 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 1 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.50 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
April 6, 1955 FDA VALEANT PHARMS LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Myasthenia gravis 89.71 58.63 13 126 609 2357337
Myasthenia gravis crisis 67.78 58.63 8 131 70 2357876

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Myasthenia gravis 117.68 49.44 17 96 594 1746074

Pharmacologic Action:

SourceCodeDescription
ATC N07AA02 NERVOUS SYSTEM
OTHER NERVOUS SYSTEM DRUGS
PARASYMPATHOMIMETICS
Anticholinesterases
FDA EPC N0000175723 Cholinesterase Inhibitor
MeSH PA D018678 Cholinergic Agents
MeSH PA D002800 Cholinesterase Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D018377 Neurotransmitter Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Myasthenia gravis indication 91637004 DOID:437
Neuromuscular Block due to Nondepolarizing Drug indication
Prevention of Nerve Agent Poisoning indication
Urinary tract obstruction contraindication 7163005 DOID:5200
Kidney disease contraindication 90708001 DOID:557
Gastrointestinal obstruction contraindication 126765001
Asthma contraindication 195967001 DOID:2841

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Acetylcholinesterase Enzyme INHIBITOR IC50 6.44 CHEMBL CHEMBL
Cholinesterase Enzyme Ki 5.46 CHEMBL
Acetylcholinesterase Enzyme Ki 4.71 CHEMBL
Acetylcholinesterase Enzyme IC50 7.09 CHEMBL

External reference:

IDSource
4019921 VUID
N0000148006 NUI
C0034261 UMLSCUI
D00487 KEGG_DRUG
59953007 SNOMEDCT_US
4019921 VANDF
9000 RXNORM
373344003 SNOMEDCT_US
d00363 MMSL
004687 NDDF
4991 PUBCHEM_CID
CHEBI:8665 CHEBI
CHEMBL812 ChEMBL_ID
CHEMBL1115 ChEMBL_ID
DB00545 DRUGBANK_ID
KVI301NA53 UNII
278 INN_ID
101-26-8 SECONDARY_CAS_RN
D011729 MESH_DESCRIPTOR_UI
8994 IUPHAR_LIGAND_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Pyridostigmine Bromide HUMAN PRESCRIPTION DRUG LABEL 1 0115-1404 TABLET, EXTENDED RELEASE 180 mg ORAL ANDA 12 sections
Pyridostigmine Bromide HUMAN PRESCRIPTION DRUG LABEL 1 0115-3511 TABLET 60 mg ORAL ANDA 12 sections
Mestinon HUMAN PRESCRIPTION DRUG LABEL 1 0187-3010 TABLET 60 mg ORAL NDA 12 sections
Mestinon HUMAN PRESCRIPTION DRUG LABEL 1 0187-3012 SOLUTION 60 mg ORAL NDA 12 sections
Mestinon HUMAN PRESCRIPTION DRUG LABEL 1 0187-3013 TABLET, EXTENDED RELEASE 180 mg ORAL NDA 12 sections
Regonol HUMAN PRESCRIPTION DRUG LABEL 1 0781-3040 INJECTION, SOLUTION 5 mg INTRAVENOUS NDA 13 sections
pyridostigmine bromide HUMAN PRESCRIPTION DRUG LABEL 1 0904-6622 TABLET 60 mg ORAL ANDA 11 sections
Pryidostigmine Bromide HUMAN PRESCRIPTION DRUG LABEL 1 13811-716 SOLUTION 60 mg ORAL ANDA 11 sections
Pyridostigmine Bromide HUMAN PRESCRIPTION DRUG LABEL 1 47781-335 TABLET, EXTENDED RELEASE 180 mg ORAL ANDA 10 sections
Pyridostigmine Bromide HUMAN PRESCRIPTION DRUG LABEL 1 50268-638 TABLET 60 mg ORAL NDA authorized generic 11 sections
Pyridostigmine Bromide HUMAN PRESCRIPTION DRUG LABEL 1 58657-810 TABLET 30 mg ORAL ANDA 12 sections
Pyridostigmine Bromide HUMAN PRESCRIPTION DRUG LABEL 1 60687-502 TABLET 60 mg ORAL ANDA 12 sections
Pyridostigmine Bromide HUMAN PRESCRIPTION DRUG LABEL 1 63739-969 TABLET 60 mg ORAL ANDA 11 sections
Pyridostigmine Bromide HUMAN PRESCRIPTION DRUG LABEL 1 64980-220 TABLET 180 mg ORAL ANDA 9 sections
Pyridostigmine Bromide HUMAN PRESCRIPTION DRUG LABEL 1 65084-999 TABLET 60 mg ORAL ANDA 11 sections
pyridostigmine bromide HUMAN PRESCRIPTION DRUG LABEL 1 65841-819 TABLET 60 mg ORAL ANDA 11 sections
Pyridostigmine Bromide HUMAN PRESCRIPTION DRUG LABEL 1 66689-406 SOLUTION 60 mg ORAL ANDA 11 sections
Pyridostigmine Bromide HUMAN PRESCRIPTION DRUG LABEL 1 68071-5032 TABLET, EXTENDED RELEASE 180 mg ORAL ANDA 12 sections
Pyridostigmine Bromide HUMAN PRESCRIPTION DRUG LABEL 1 68084-494 TABLET 60 mg ORAL ANDA 12 sections
pyridostigmine bromide HUMAN PRESCRIPTION DRUG LABEL 1 68382-659 TABLET 60 mg ORAL ANDA 11 sections
pyridostigmine bromide HUMAN PRESCRIPTION DRUG LABEL 1 68682-301 TABLET, EXTENDED RELEASE 180 mg ORAL NDA authorized generic 11 sections
Pyridostigmine Bromide HUMAN PRESCRIPTION DRUG LABEL 1 68682-302 TABLET 60 mg ORAL NDA authorized generic 11 sections
pyridostigmine bromide HUMAN PRESCRIPTION DRUG LABEL 1 68682-307 SOLUTION 60 mg ORAL NDA authorized generic 12 sections
Pyridostigmine Bromide HUMAN PRESCRIPTION DRUG LABEL 1 69238-1731 SOLUTION 60 mg ORAL ANDA 11 sections
Pyridostigmine HUMAN PRESCRIPTION DRUG LABEL 1 70954-148 SOLUTION 60 mg ORAL ANDA 11 sections
Pyridostigmine Bromide HUMAN PRESCRIPTION DRUG LABEL 1 71930-028 TABLET 60 mg ORAL ANDA 11 sections
Pyridostigmine Bromide HUMAN PRESCRIPTION DRUG LABEL 1 72458-128 TABLET 30 mg ORAL NDA 19 sections